Urinary Bladder, Overactive [clinicaltrials_resource:06060cf48ce2b56251cd3acb6989e051]
A Double-Blind, Paralleled Study Comparing Efficacy/Safety of Solifenacin to Tolterodine in Overactive Bladder Patients [clinicaltrials:NCT00368706]clinicaltrials:NCT00454740clinicaltrials:NCT00454896clinicaltrials:NCT00463541Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder [clinicaltrials:NCT00479505]A Study of YM178 in Patients With Symptomatic Overactive Bladder [clinicaltrials:NCT00527033]clinicaltrials:NCT00573508clinicaltrials:NCT00613327A Study to Evaluate the Efficacy of Tolterodine on Specific Symptoms in Adult Patients With Overactive Bladder. [clinicaltrials:NCT00645281]A Study to Evaluate the Efficacy of Tolterodine Prolonged Release Compared With Propiverine for the Treatment of Korean Patients With Overactive Bladder as Assessed by Ambulatory Urodynamic Monitoring [clinicaltrials:NCT00646880]clinicaltrials:NCT00662909Linkage Analysis in Interstitial Cystitis [clinicaltrials:NCT00675298]clinicaltrials:NCT00688688clinicaltrials:NCT00689104A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder [clinicaltrials:NCT00699049]clinicaltrials:NCT00795509clinicaltrials:NCT00798434clinicaltrials:NCT00801944clinicaltrials:NCT00802373Pulsed Electromagnetic Stimulation for Treatment of Overactive Bladder [clinicaltrials:NCT00805779]clinicaltrials:NCT00806494A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031 [clinicaltrials:NCT00814736]A Long-term Study of YM178 in Symptomatic Overactive Bladder Patients [clinicaltrials:NCT00840645]516-BOTOX Urinary Incontinence Detrusor [clinicaltrials:NCT00850733]clinicaltrials:NCT00912964The Effect Of Fesoterodine On Pharmacokinetics And Pharmacodynamics Of Warfarin In Healthy Subjects [clinicaltrials:NCT00914667]clinicaltrials:NCT00928395clinicaltrials:NCT00966004Cohort Study: Perceptual Urge Sensation [clinicaltrials:NCT00971646]Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency [clinicaltrials:NCT00979472]Evaluation of Adherence to Solifenacin Treatment in Overactive Bladder Patients [clinicaltrials:NCT00985387]A Study of YM178 in Subjects With Symptoms of Overactive Bladder [clinicaltrials:NCT01043666]clinicaltrials:NCT01054222clinicaltrials:NCT01091519clinicaltrials:NCT01157377clinicaltrials:NCT01194999Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents [clinicaltrials:NCT01262391]clinicaltrials:NCT01302054A Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder (OAB) (MK-4618-008 AM3 EXT1[AM2]) [clinicaltrials:NCT01314872]clinicaltrials:NCT01340027
condition [clinicaltrials_vocabulary:condition]
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [clinicaltrials:NCT00127270]clinicaltrials:NCT00131573A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder [clinicaltrials:NCT00137397]Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome [clinicaltrials:NCT00138723]Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women [clinicaltrials:NCT00143481]clinicaltrials:NCT00168454A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder [clinicaltrials:NCT00170755]A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. [clinicaltrials:NCT00171145]Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder [clinicaltrials:NCT00171184]clinicaltrials:NCT00174798A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder [clinicaltrials:NCT00189800]Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder [clinicaltrials:NCT00196404]A Cost Analysis of Interstim Therapy [clinicaltrials:NCT00200031]Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan [clinicaltrials:NCT00212706]Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan [clinicaltrials:NCT00212732]NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder [clinicaltrials:NCT00213577]A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome [clinicaltrials:NCT00220363]Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome [clinicaltrials:NCT00220376]Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase [clinicaltrials:NCT00220389]Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome [clinicaltrials:NCT00220402]clinicaltrials:NCT00224016clinicaltrials:NCT00224029Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder [clinicaltrials:NCT00224146]Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication. [clinicaltrials:NCT00230789]Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. [clinicaltrials:NCT00231491]A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) [clinicaltrials:NCT00231790]Programmable Timer in the Bladder Rehabilitation Treatment of OAB [clinicaltrials:NCT00238680]Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. [clinicaltrials:NCT00262496]Surface Nerve Stimulation Treatment for OAB in Children [clinicaltrials:NCT00282490]Detrol LA In Men With Overactive Bladder. [clinicaltrials:NCT00282932]A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder [clinicaltrials:NCT00290563]Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder [clinicaltrials:NCT00293839]clinicaltrials:NCT00311376Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome [clinicaltrials:NCT00313924]A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder [clinicaltrials:NCT00321477]Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients [clinicaltrials:NCT00332319]Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity [clinicaltrials:NCT00335660]A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) [clinicaltrials:NCT00337090]clinicaltrials:NCT00337558Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms [clinicaltrials:NCT00343486]
condition browse [clinicaltrials_vocabulary:condition-browse]
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder [clinicaltrials:NCT00127270]clinicaltrials:NCT00131573A Study to Measure the Effect of Tolterodine Extended Release on the Thickness of the Bladder Wall in Patients With Overactive Bladder [clinicaltrials:NCT00137397]Trial to Investigate the Efficacy, Tolerability and Safety of Fesoterodine Sustained Release in Subjects With Overactive Bladder Syndrome [clinicaltrials:NCT00138723]Effect of Detrol LA on Overactive Bladder Symptoms, Sexual Quality of Life and Sexual Function in Women [clinicaltrials:NCT00143481]clinicaltrials:NCT00168454A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder [clinicaltrials:NCT00170755]A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder. [clinicaltrials:NCT00171145]Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder [clinicaltrials:NCT00171184]clinicaltrials:NCT00174798A Study of Solifenacin Succinate Compared to Tolterodine in Patients With Overactive Bladder [clinicaltrials:NCT00189800]Study to Evaluate the Safety and Efficacy of DR-3001 Versus Placebo in Women With Overactive Bladder [clinicaltrials:NCT00196404]A Cost Analysis of Interstim Therapy [clinicaltrials:NCT00200031]Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan [clinicaltrials:NCT00212706]Controlled Study of ONO-8025 (KRP-197) in Patients With Overactive Bladder in Japan [clinicaltrials:NCT00212732]NEUROTOX: Two Dosages of Type A Botulinic Toxin in Neurogenic Overactive Bladder [clinicaltrials:NCT00213577]A Multicenter Trial to Investigate Fesoterodine Sustained Release in Overactive Bladder Syndrome [clinicaltrials:NCT00220363]Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome [clinicaltrials:NCT00220376]Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase [clinicaltrials:NCT00220389]Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP583) for the Treatment of Overactive Bladder Syndrome [clinicaltrials:NCT00220402]clinicaltrials:NCT00224016clinicaltrials:NCT00224029Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder [clinicaltrials:NCT00224146]Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication. [clinicaltrials:NCT00230789]Efficacy and Safety of Botulinum Toxin A for the Treatment of Refractory Overactive Bladder. [clinicaltrials:NCT00231491]A Placebo-Controlled Study of MK0634 in Patients With Overactive Bladder (0634-007) [clinicaltrials:NCT00231790]Programmable Timer in the Bladder Rehabilitation Treatment of OAB [clinicaltrials:NCT00238680]Botulinum-A Toxin Injection for Detrusor Hyperreflexia in Spinal Cord Injury: A Non-Surgical Approach. [clinicaltrials:NCT00262496]Surface Nerve Stimulation Treatment for OAB in Children [clinicaltrials:NCT00282490]Detrol LA In Men With Overactive Bladder. [clinicaltrials:NCT00282932]A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase II Study of MK0594 in Patients With Overactive Bladder [clinicaltrials:NCT00290563]Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder [clinicaltrials:NCT00293839]clinicaltrials:NCT00311376Assessing the OAB-8 Questionnaire as a Tool to Measure Treatment Outcome [clinicaltrials:NCT00313924]A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder [clinicaltrials:NCT00321477]Effects Of GW679769 On Bladder Nerve Function And Symptoms Of Overactive Bladder In Spinal Cord Injury Patients [clinicaltrials:NCT00332319]Safety and Efficacy of AV608 in Subjects With Idiopathic Detrusor Overactivity [clinicaltrials:NCT00335660]A Study of YM178 in Patients With Symptomatic Overactive Bladder (DRAGON) [clinicaltrials:NCT00337090]clinicaltrials:NCT00337558Dose Ranging Study Of Solabegron Versus Placebo In Female Patients With Overactive Bladder Symptoms [clinicaltrials:NCT00343486]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
Urinary Bladder, Overactive [clinicaltrials_resource:06060cf48ce2b56251cd3acb6989e051]
Bio2RDF identifier
06060cf48ce2b56251cd3acb6989e051
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:06060cf48ce2b56251cd3acb6989e051
identifier
clinicaltrials_resource:06060cf48ce2b56251cd3acb6989e051
title
Urinary Bladder, Overactive
@en
type
label
Urinary Bladder, Overactive [clinicaltrials_resource:06060cf48ce2b56251cd3acb6989e051]
@en
Urinary Bladder, Overactive